Vaxcyte, Inc. (NASDAQ:PCVX) Holdings Decreased by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC reduced its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 3.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 156,056 shares of the company’s stock after selling 6,376 shares during the period. Segall Bryant & Hamill LLC’s holdings in Vaxcyte were worth $17,833,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Riverview Trust Co acquired a new stake in shares of Vaxcyte during the 3rd quarter valued at $27,000. Blue Trust Inc. raised its holdings in shares of Vaxcyte by 33.5% during the third quarter. Blue Trust Inc. now owns 371 shares of the company’s stock worth $42,000 after acquiring an additional 93 shares in the last quarter. Fifth Third Bancorp purchased a new stake in shares of Vaxcyte during the second quarter worth $35,000. J.Safra Asset Management Corp boosted its position in Vaxcyte by 649.4% during the second quarter. J.Safra Asset Management Corp now owns 607 shares of the company’s stock valued at $46,000 after purchasing an additional 526 shares during the last quarter. Finally, Meeder Asset Management Inc. grew its stake in Vaxcyte by 1,007.9% in the third quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock valued at $80,000 after purchasing an additional 635 shares in the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on PCVX. Jefferies Financial Group lifted their price target on Vaxcyte from $108.00 to $129.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Mizuho lifted their target price on shares of Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a research note on Tuesday, September 10th. Leerink Partners increased their price target on shares of Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Finally, Needham & Company LLC reissued a “buy” rating and set a $140.00 target price on shares of Vaxcyte in a research report on Wednesday, November 6th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Vaxcyte presently has a consensus rating of “Buy” and a consensus price target of $147.50.

Vaxcyte Stock Down 1.3 %

Shares of PCVX stock opened at $85.96 on Thursday. Vaxcyte, Inc. has a 12 month low of $48.24 and a 12 month high of $121.06. The company has a market cap of $10.71 billion, a PE ratio of -18.69 and a beta of 1.01. The business’s 50 day moving average is $108.95 and its two-hundred day moving average is $89.11.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter last year, the business earned ($0.91) earnings per share. As a group, equities analysts expect that Vaxcyte, Inc. will post -4.14 EPS for the current fiscal year.

Insider Activity

In other news, CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $115.94, for a total value of $927,520.00. Following the completion of the sale, the chief financial officer now directly owns 90,383 shares of the company’s stock, valued at approximately $10,479,005.02. This represents a 8.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Elvia Cowan sold 5,000 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $107.67, for a total transaction of $538,350.00. Following the completion of the sale, the senior vice president now owns 12,723 shares of the company’s stock, valued at approximately $1,369,885.41. The trade was a 28.21 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 117,464 shares of company stock valued at $12,640,276. 3.10% of the stock is owned by insiders.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.